目的 探討替比夫定片對慢性乙肝患者細胞免疫功能的影響。方法 選取西安市北方醫(yī)院2014年1月-2015年5月收治的慢性乙肝患者126例,根據(jù)隨機數(shù)字表法分為治療組與對照組各63例,對照組口服恩替卡韋治療,治療組口服替比夫定治療,治療觀察周期為3個月。結(jié)果 治療后治療組的HBV DNA轉(zhuǎn)陰率和HBeAg陰轉(zhuǎn)率分別為95.2%和71.4%,對照組為81.0%和44.4%,組間對比差異均有統(tǒng)計學(xué)意義(P<0.05)。治療后治療組與對照組的ALT值分別為(46.09±15.98)U/L和(76.13±19.55)U/L,都明顯低于治療前的(153.20±33.01)U/L和(151.30±26.02)U/L(P<0.05),且治療組降低程度更多,與對照組比較差異明顯(P<0.05)。兩組治療后的血清IL-2值明顯上升(P<0.05),而IL-4值明顯降低(P<0.05),同時治療后治療組的血清IL-2與IL-4值與對照組相比差異也有統(tǒng)計學(xué)意義(P<0.05)。治療后治療組與對照組的血CD4⁺CD25⁺值分別為(2.22±1.02)%和(3.45±0.98)%,都明顯低于治療前的(4.87±1.22)%和(4.89±1.02)%(P<0.05),同時組間對比差異明顯(P<0.05)。結(jié)論 替比夫定片治療慢性乙肝患者能有效提高機體細胞免疫功能,降低血清炎癥因子的表達,有利于抑制乙肝病毒的復(fù)制與肝功能的恢復(fù),有很好的應(yīng)用價值。

Objective To investigate the effects of Telbivudine Tablets in cells immune function of chronic hepatitis B patients. Methods Totally 126 cases of chronic hepatitis B from January 2014 to May 2015 in the Northern Hospital of Xi'an City were selected and randomly divided into treatment and control groups with 63 cases in each group. The patients in control group were treated with Entecavir, the patients in treatment group were treated with Telbivudine. The treatment continued for 3 months. Results After treatment, the HBV DNA negative rate and the HBeAg negative conversion rate of the treatment group were 95.2% and 71.4%, while those in the control group were 81.0% and 44.4%, and the differences between the groups were statistically significant (P<0.05). The ALT values of treatment group and control group after treatment were (46.09±15.98) U/L and (76.13±19.55) U/L that were significantly lower than (153.20±33.01) U/L and (151.30±26.02) U/L (P<0.05) before treatment, while the differences between the two groups were statistically significant (P<0.05). The serum IL-2 values increased significantly after treatment (P<0.05), while IL-4 values were significantly lower after treatment (P<0.05), while the serum IL-2 and IL-4 values in the treatment group after treatment compared with the control group were significant differences (P<0.05). The blood CD4⁺ and CD25⁺ values in the treatment group and control group after treatment were (2.22±1.02)% and (3.45±0.98)% that were significantly lower than those before treatment of (4.87±1.22)% and (4.89±1.02)% (P<0.05), while differences between the two groups were significant (P<0.05). Conclusion Telbivudine Tablets in the treatment of chronic hepatitis B patients can improve immune function, reduce the expression of inflammatory factors will help restore suppression of HBV replication and liver function that has very good values.